生物活性

KT172 is a Diacylglycerol lipase (DAGL) inhibitor selective for DAGLβ. Diacylglycerol lipases DAGLα and DAGLβ are serine hydrolases that biosynthesize the endocannabinoid 2-arachidonoylglycerol (2-AG). A lack of selective inhibitors has hampered study of these lipases. KT172 is a new potent and selective DAGLβ inhibitor with an IC₅₀of 60 nM for recombinant DAGLβ vs 140 nM for DAGLα, although it is not active against DAGLαin vivo, and negligible activity against FAAH, MGLL and ABHD11, other key enzymes involved in endocannabinoid signaling or against cytosolic phospholipase A2 (cPLA2 or PLA2G4A). The main off target inhibition against ABHD6 (IC₅₀values of 5 nM) can be controlled for by use of the related compounds, KT195SML1308or KT185SML1249, potent and selective ABDH6 inhibitors with negligible activity against DAGLβ. KT172 disrupts the lipid network involved in macrophage inflammatory responses, lowering 2-AG, as well as arachidonic acid and eicosanoids, in mouse peritoneal macrophages.

化学数据

不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

例如，依据体表面积折算法，将化合物用于小鼠的剂量20 mg/kg 换算成大鼠的剂量，需要将20 mg/kg 乘以小鼠的K_m系数（3），再除以大鼠的K_m系数（6），得到化合物用于大鼠的等效剂量为10 mg/kg。

储备液配制

以下数据基于产品分子量，对于特殊产品，请参照COA中的储备液配制条件和说明进行操作。